RESPONSE-ADAPTIVE STEREOTACTIC BODY RADIOTHERAPY BOOST AFTER CONCURRENT CHEMORADIOTHERAPY IN UNRESECTABLE STAGE III NSCLC: A PROSPECTIVE SINGLE-CENTRE COHORT STUDY.
OBJECTIVE This study aimed to escalate the dose to the residual primary tumor with an adaptive stereotactic body radiotherapy (SBRT) boost after concurrent chemoradiotherapy (CRT) in unresectable stage III non-small cell lung cancer (NSCLC), and to explore, within this cohort, whether a higher cumulative dose to the re...